MX2017012430A - Formas solvatadas de un inhibidor de tirosina quinasa de bruton. - Google Patents

Formas solvatadas de un inhibidor de tirosina quinasa de bruton.

Info

Publication number
MX2017012430A
MX2017012430A MX2017012430A MX2017012430A MX2017012430A MX 2017012430 A MX2017012430 A MX 2017012430A MX 2017012430 A MX2017012430 A MX 2017012430A MX 2017012430 A MX2017012430 A MX 2017012430A MX 2017012430 A MX2017012430 A MX 2017012430A
Authority
MX
Mexico
Prior art keywords
bruton
tyrosine kinase
solvates
conditions
kinase inhibitor
Prior art date
Application number
MX2017012430A
Other languages
English (en)
Inventor
Stephen Smyth Mark
Goldman Erick
Bonnaud Thierry
Munoz Garcia Alberto
Peter Worrall Christopher
Original Assignee
Pharmacyclics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacyclics Llc filed Critical Pharmacyclics Llc
Publication of MX2017012430A publication Critical patent/MX2017012430A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N23/00—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00
    • G01N23/20—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00 by using diffraction of the radiation by the materials, e.g. for investigating crystal structure; by using scattering of the radiation by the materials, e.g. for investigating non-crystalline materials; by using reflection of the radiation by the materials
    • G01N23/20075—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00 by using diffraction of the radiation by the materials, e.g. for investigating crystal structure; by using scattering of the radiation by the materials, e.g. for investigating non-crystalline materials; by using reflection of the radiation by the materials by measuring interferences of X-rays, e.g. Borrmann effect

Abstract

En la presente se describen solvatos del inhibidor de la tirosina quinasa de Bruton (Btk) 1-( (R)-3-(4-amino-3-(4- fenoxifenil)-1H-pirazolo[3,4-d]pirimidin-1-il)piperidin-1-il)prop -2-en-1-ona, que incluyen las formas cristalinas y sales aceptables desde el punto de vista farmacóutico. Tambión se describen composiciones que incluyen los solvatos, así­ como los métodos de uso de los solvatos, solos o en combinación con otros agentes terapóuticos, para el tratamiento de enfermedades o afecciones autoinmunitarias, enfermedades o afecciones heteroinmunitarias, cáncer, que incluye linfoma, y enfermedades o afecciones inflamatorias.
MX2017012430A 2015-03-27 2016-03-25 Formas solvatadas de un inhibidor de tirosina quinasa de bruton. MX2017012430A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562139594P 2015-03-27 2015-03-27
PCT/US2016/024305 WO2016160598A1 (en) 2015-03-27 2016-03-25 Solvated forms of a bruton's tyrosine kinase inhibitor

Publications (1)

Publication Number Publication Date
MX2017012430A true MX2017012430A (es) 2018-07-06

Family

ID=57006292

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017012430A MX2017012430A (es) 2015-03-27 2016-03-25 Formas solvatadas de un inhibidor de tirosina quinasa de bruton.

Country Status (11)

Country Link
US (4) US20180072738A1 (es)
EP (1) EP3273961A4 (es)
JP (2) JP2018509457A (es)
CN (1) CN107530346A (es)
AU (1) AU2016243116A1 (es)
BR (1) BR112017020744A2 (es)
CA (1) CA2981048A1 (es)
HK (2) HK1248147A1 (es)
MA (1) MA41827A (es)
MX (1) MX2017012430A (es)
WO (1) WO2016160598A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220093389A (ko) 2012-06-04 2022-07-05 파마싸이클릭스 엘엘씨 브루톤 타이로신 키나아제 저해제의 결정 형태
DK3265084T3 (da) 2015-03-03 2024-02-12 Pharmacyclics Llc Farmaceutiske formuleringer af Bruton's tyrosinkinase-hæmmer
WO2017029586A1 (en) 2015-08-19 2017-02-23 Sun Pharmaceutical Industries Limited Crystalline forms of ibrutinib
CZ2016276A3 (cs) * 2016-05-11 2017-11-22 Zentiva, K.S. Pevné formy volné báze ibrutinibu
US10183024B2 (en) 2016-12-02 2019-01-22 Apotex Inc. Crystalline forms of ibrutinib
CZ2017787A3 (cs) 2017-12-08 2019-06-19 Zentiva, K.S. Farmaceutické kompozice obsahující ibrutinib
EP3575300A1 (en) 2018-05-31 2019-12-04 Apotex Inc. Novel crystalline forms of ibrutinib
US10688050B1 (en) 2018-12-21 2020-06-23 Synthon B.V. Pharmaceutical composition comprising ibrutinib
EP3669867A1 (en) 2018-12-21 2020-06-24 Synthon B.V. Pharmaceutical composition comprising ibrutinib
WO2023242384A1 (en) 2022-06-17 2023-12-21 Krka, D.D., Novo Mesto Crystalline form of ibrutinib

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
DE3303707A1 (de) * 1983-02-04 1984-08-09 Dynamit Nobel Ag, 5210 Troisdorf Verfahren zur spaltung von organosiloxanen und dessen produkte und anwendungen
US4624848A (en) 1984-05-10 1986-11-25 Ciba-Geigy Corporation Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
US4968509A (en) 1987-07-27 1990-11-06 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
IL92966A (en) 1989-01-12 1995-07-31 Pfizer Hydrogel-operated release devices
DE69222847T3 (de) 1991-04-16 2005-09-15 Nippon Shinyaku Co., Ltd. Verfahren zur herstellung einer festen dispersion
KR100274734B1 (ko) 1991-11-22 2000-12-15 제이코버스 코넬리스 레이서 리제드로네이트 지연-방출성 조성물
US5461140A (en) 1992-04-30 1995-10-24 Pharmaceutical Delivery Systems Bioerodible polymers for solid controlled release pharmaceutical compositions
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
WO1994008568A1 (en) 1992-10-16 1994-04-28 Nippon Shinyaku Co., Ltd. Method of manufacturing wax matrices
US5686105A (en) 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
US6326469B1 (en) 1994-04-22 2001-12-04 Sugen, Inc. Megakaryocytic protein tyrosine kinases
CA2220451A1 (en) 1995-05-17 1996-11-21 Cedars-Sinai Medical Center Methods and compositions for improving digestion and absorption in the small intestine
CO5210907A1 (es) * 1999-05-12 2002-10-30 Novartis Ag Solvatos de pometrozina, insecticidamente activos, composiciones que contienen estos compuestos y metodos tanto para producir dichos compuestos y composiciones como para controlar plagas animales con estas composiciones
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
GB0108903D0 (en) * 2000-10-05 2001-05-30 Aventis Pharm Prod Inc Novel crystalline forms of a factor Xa inhibitor
US6465014B1 (en) 2001-03-21 2002-10-15 Isp Investments Inc. pH-dependent sustained release, drug-delivery composition
EP1664762A4 (en) 2003-09-03 2008-08-13 Us Gov Health & Human Serv METHODS OF IDENTIFICATION, DIAGNOSIS AND PREDICTION FOR LYMPHOMES SURVIVAL
SI2530083T1 (sl) 2006-09-22 2016-09-30 Pharmacyclics Llc Inhibitorji Bruton tirozin kinaze
ES2562215T3 (es) * 2007-03-28 2016-03-03 Pharmacyclics Llc Inhibidores de la tirosina quinasa de Bruton
US8541391B2 (en) * 2010-10-28 2013-09-24 Viropharma Incorporated Crystalline phases of 5,6-dichloro-2-(isopropylamino)-1-β-L-ribofuranosyl-1H-benzimidazole
US8501484B2 (en) * 2011-03-14 2013-08-06 Los Alamos National Security, Llc Preparation of cerium halide solvate complexes
KR20220093389A (ko) * 2012-06-04 2022-07-05 파마싸이클릭스 엘엘씨 브루톤 타이로신 키나아제 저해제의 결정 형태
MX369503B (es) * 2013-04-08 2019-11-11 Pharmacyclics Llc Combinaciones que comprenden ibrutinib y abt-199 para tratar trastornos proliferativos de células b y métodos de uso de las mismas.
CN106008515A (zh) * 2014-01-29 2016-10-12 苏州晶云药物科技有限公司 依鲁替尼的新晶型及其制备方法

Also Published As

Publication number Publication date
CA2981048A1 (en) 2016-10-06
BR112017020744A2 (pt) 2018-07-17
WO2016160598A1 (en) 2016-10-06
JP2022033783A (ja) 2022-03-02
HK1248147A1 (zh) 2018-10-12
EP3273961A4 (en) 2018-10-31
EP3273961A1 (en) 2018-01-31
CN107530346A (zh) 2018-01-02
US20220106317A1 (en) 2022-04-07
US20200347063A1 (en) 2020-11-05
MA41827A (fr) 2018-01-30
JP2018509457A (ja) 2018-04-05
US20190367519A1 (en) 2019-12-05
HK1249737A1 (zh) 2018-11-09
US20180072738A1 (en) 2018-03-15
AU2016243116A1 (en) 2017-10-19

Similar Documents

Publication Publication Date Title
JOP20200222A1 (ar) أشكال كريستالين لمثبط أنزيم كيناز تيروسين بروتون
MX2021015405A (es) Composiciones farmaceuticas de un inhibidor de tirosina cinasa de bruton.
MX2017012430A (es) Formas solvatadas de un inhibidor de tirosina quinasa de bruton.
MX2017012411A (es) Co-cristales de un inhibidor de tirosina cinasa de bruton.
MX2017001671A (es) Formulaciones novedosas de un inhibidor de la tirosina cinasa de bruton.
PH12020552065A1 (en) Ibrutinib combination therapy
MX2017015574A (es) Inhibidores de tirosina quinasa de bruton.
MX2020010412A (es) Inhibidores de tirosina quinasa de bruton.
EA201790995A1 (ru) ЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-a]ПИРИМИДИНЫ И ИХ ПРИМЕНЕНИЕ ПРИ ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ
TW201613919A (en) Inhibitors of Bruton's tyrosine kinase
MX2014010590A (es) Terapia de combinacion para trastornos proliferativos.
TN2018000321A1 (en) 1,5-dihydr0-4h-pyrazol0[3,4-d]pyrimidin-4-0nes and 1,5-dihydr0-4h-pyrazol0[4,3-c]pyridin-4-0nes as pde1 inhibitors.
PH12020552274A1 (en) Formulations of an axl/mer inhibitor
WO2018033941A3 (en) Pharmaceutical compositions of ibrutinib
WO2019014322A8 (en) KINASE INHIBITORS FOR THE TREATMENT OF DISEASES
MX2019000159A (es) Pirrolo[2,3-d]piridazin-4-onas sustituidas y pirazolo[3,4-d]pirida zin-4-onas como inhibidores de la proteina quinasa.
MA41643B1 (fr) Formulations pharmaceutiques d'inhibiteur de la tyrosine kinase de bruton
MX2016011674A (es) Combinacion que comprende un inhibidor de btk y un inhibidor de akt.